Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:08:27.158Z.
Calculation as of: 2026-10-06T17:08:27.158Z.
Quote observation: 2026-10-06T17:05:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$212.93M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.12M
Price/OCF Ratio
35.99
TTM Avg
45.91
3Y Avg
60.75
5Y Avg
60.42
Market Cap
$208.14M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.87M
Price/OCF Ratio
N/A
TTM Avg
10.01
3Y Avg
10.01
5Y Avg
10.01
Market Cap
$217.70M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $212.93M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.12M | 35.99 | 45.91 | 60.75 | 60.42 |
| Alector, Inc. (ALEC)vs › | $209.84M | N/A | 3.18 | 3.20 | 4.43 |
| Compugen Ltd. (CGEN)vs › | $210.38M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $208.14M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.87M | N/A | 10.01 | 10.01 | 10.01 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $217.70M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.51M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.06M | 28.45 | 26.60 | 21.85 | 26.58 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $221.15M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
